Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

ATI Engage wins Digital Learning Innovation Award for advancing nursing education with AI-powered platform.

Others
11 Jun 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Ascend Learning's ATI Engage® Series won the Digital Learning Innovation Award at the 2026 EdTech Breakthrough Awards for its advanced digital platform that enhances nursing education. The platform uses AI to personalize learning, offering interactive case studies and real-time feedback to help students build clinical judgment and readiness. This recognition highlights the growing importance of innovative, technology-driven education tools in preparing practice-ready nurses. The award signals continued investment in digital solutions that improve healthcare training outcomes globally.

More News (ASND)

Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock.

Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock.

Ascendis Pharma reported positive five-year results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) for adult hypoparathyroidism. The therapy maintained stable calcium levels, kidney and bone health, and quality of life, all...

Company Fundamentals
Bullish
39 minutes ago
Touchstone Mid Cap Growth Fund beats Russell Midcap Growth Index in Q1 2026.

Touchstone Mid Cap Growth Fund beats Russell Midcap Growth Index in Q1 2026.

The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Key contributors to this strong performance included Vertiv Holdings, Ascendis Pharma,...

Market News
Neutral
7 hours ago
5-year data show TransCon PTH sustains multi-organ benefits and quality of life in hypoparathyroidism patients

5-year data show TransCon PTH sustains multi-organ benefits and quality of life in hypoparathyroidism patients

Ascendis Pharma announced 5-year Phase 2 trial results for TransCon PTH, showing sustained efficacy and safety in adults with hypoparathyroidism. The treatment replicated natural parathyroid hormone effects, improving kidney function, calcium levels,...

Company Fundamentals
Bullish
1 day ago
Ascendis Pharma to present new data on rare endocrine disease treatments at ENDO 2026 conference.

Ascendis Pharma to present new data on rare endocrine disease treatments at ENDO 2026 conference.

Ascendis Pharma announced it will share new clinical trial data on treatments for rare endocrine diseases including hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency at the ENDO 2026 conference in Chicago. The presentations ...

Market News
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App